Legal & General Group Plc Has $40.07 Million Holdings in Solventum Corporation $SOLV

Legal & General Group Plc cut its holdings in Solventum Corporation (NYSE:SOLV) by 3.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 528,397 shares of the company’s stock after selling 18,900 shares during the period. Legal & General Group Plc’s holdings in Solventum were worth $40,074,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Strengthening Families & Communities LLC lifted its position in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after buying an additional 260 shares during the last quarter. Barrett & Company Inc. increased its holdings in shares of Solventum by 206.2% during the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the last quarter. IMG Wealth Management Inc. bought a new position in shares of Solventum in the 2nd quarter valued at approximately $31,000. Smartleaf Asset Management LLC lifted its holdings in Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after purchasing an additional 352 shares during the last quarter. Finally, MTM Investment Management LLC acquired a new stake in Solventum in the 2nd quarter worth approximately $40,000.

Solventum Price Performance

NYSE:SOLV opened at $85.37 on Thursday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum Corporation has a one year low of $60.70 and a one year high of $86.81. The company has a fifty day moving average price of $73.34 and a 200 day moving average price of $73.49. The stock has a market cap of $14.81 billion, a P/E ratio of 9.84, a PEG ratio of 9.05 and a beta of 0.48.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum declared that its board has approved a stock repurchase plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to buy up to 7.5% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several analyst reports. Wells Fargo & Company increased their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. Jefferies Financial Group began coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Piper Sandler lifted their target price on shares of Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $85.56.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.